Business France Healthcare - North America’s Post

🔬 Senda Biosciences Raises $123M Series C in Strategic Move TL;DR: • Total funding now at $266M since inception • Plans for clinical trials by end of 2022 • Focus on intersystems biology platform • Strong backing from Flagship Pioneering In a bold move amid market volatility, Senda Biosciences has secured $123M in Series C funding, showcasing investor confidence in their innovative intersystems biology platform. While the biotech IPO market cools (only 15 drug developers went public in 2022 vs. 81 last year), Senda's strategic decision to remain private demonstrates mature market awareness. Key Developments: • Leveraging ML tools to decode biochemical signals • Targeting infectious diseases, metabolic disorders, and cancer • Ongoing collaboration with Nestlé Health Science • Developing oral alternatives to injectable drugs "Great science and great data always attract investors," notes CEO Guillaume Pfefer, highlighting Senda's commitment to scientific excellence over market timing. 💭 What are your thoughts on private funding vs. IPO strategies in today's biotech landscape? Share your insights below. #Biotech #VentureCapital #Innovation #LifeSciences #BiotechFunding #intelligencesimplified #pharma #biotech #biodatastudio

James R Kean, MBA, CEO of Molecular You, will present on the company’s multi-biomarker analytics platform. As the first and only platform of its kind, Molecular You provides #clinicians with decision support and highly accurate predictive risk profiles across 26+ health areas. Based in Vancouver, Molecular You aims to transform healthcare with advanced bioinformatics and a focus on longevity and healthspan.

🎉 Exciting News! iProtics Collaborates with Biotech Booster and Leiden University! 🧬 We're thrilled to announce our latest project, "Immunoshreder," a groundbreaking collaboration between iProtics, Leiden University, and Biotech Booster. This initiative, backed by a €200,000 grant, marks a significant milestone in our journey to revolutionize immunoproteasome inhibition. Key highlights: • Focus: Validating iProtics' immunoproteasome inhibitors in the pre-clinical phase • Partners: Leiden University and Biotech Booster • Funding: €200,000 grant This Biotech Booster grant significantly accelerates our development efforts, complementing our previous investments from UNIIQ and NWO Faculty of Impact. Stay tuned for updates as we embark on this exciting new chapter! #Biotechnology #Innovation #ResearchCollaboration #iProtics #BiotechBooster #ProteasomeInhibitor #DrugDevelopment

Excited to have led the closing panel entitled "Bridging Science and Investment" in San Diego, CA. Joined by Dr. Sanjeev Thohan (Cogentis Therapeutics, Inc./Phoenix Molecular Designs) and Dr. Yuhua Ji (Grace Science, LLC ), we explored the intersection of scientific innovation and investment strategies. Key topics of this thought-provoking panel included: - Strategic investment approaches in the evolving biotech landscape - The critical role of venture capital in accelerating drug discovery - Innovative funding models for cutting-edge pharmaceutical research - The future of biotechnologies and the investment opportunities they present Thank you to the panelists for sharing their invaluable insights. Our discussion underscored the vital role of strategic investments in driving innovation and shaping the future of drug discovery and development. Together, we are paving the way for groundbreaking advancements in biotech. #biotechnology #MedicinalChemistry, #strategy #drugdevelopment Proventa International #Bio2024 BIO International Convention #DrugDiscovery #Investment #VentureCapital #Biotech #SanDiego American Association for Precision Medicine (AAPM) WISE World Investors & Entrepreneurs Society Agility Pharmaceuticals Precision BioPharma #ai #news

🔬 Big news for the #LifeSciences ecosystem in Barcelona-Catalonia! 🧪The German biotech QIAGEN is set to invest €13 million over the next five years to expand its facilities in Barcelona. 🥼This investment will create a global innovation center dedicated to advancing molecular diagnostics for infectious diseases, opening in early 2026. Over 400 high-value jobs are expected to be generated in the long term. 🤝This initiative is supported by Catalonia Trade & Investment. We help companies establish themselves in #Catalonia and offer continuous support for their operations! Read the news👇 https://lnkd.in/dcBztBiB #Barcelona #Innovation #Biotechnology #Healthcare #LifeSciences

Swiss biotech continues to do well

At this year’s Galien Forum, we focused on transformative shifts in the biopharma industry, especially in the wake of COVID-19. Our discussions highlighted how intelligent technologies and AI are driving advances in drug discovery, reducing investment risks, and enabling personalized healthcare - paving the way for faster access to medicines and better economic outcomes for companies and healthcare systems alike. We also explored new collaboration models with biotech and academia, while expanding our scope beyond oncology to address metabolic diseases and neuro-related conditions. Insights on aging populations and constrained healthcare budgets underscored the need to keep science at the heart of our efforts as we embrace innovation. Looking ahead, these advancements inspire optimism for a healthcare ecosystem that is more efficient, accessible, and truly transformative for patient care. My heartfelt thanks to my co-host, Dr. Michael Rosenblatt, and our distinguished panelists, Dr. Noubar Afeyan, John F. Crowley, and Christopher Viehbacher, Biogen, for sharing their invaluable perspectives during the 2024 CEO Panel Discussion. Thank you all for your commitment to advancing science and healthcare. I look forward to our continued collaboration in this dynamic field! #GalienForum2024 #Biotechnology #HealthEquity

BioM Biotech Cluster Development GmbH’s highly anticipated event #BayOConnect - Forum for Biotech & LifeScience is coming up in Munich for the next two days! On July 2 the focus will be how to “Connect to Investment”, while on July 3, the spotlight will be on one of the biggest trends in Life Sciences exploring how to “Connect to AI”.   You won’t want to miss out on these program highlights featuring our clients:   “Risk and Reward - Comparative Strategies in Biotech Funding” June 2, 1:30 PM, with Olivier Litzka of Andera Partners   “Spotlight: Are we ready for AI?” June 3, 2:10 PM, with Dr. Friedrich von Bohlen of Molecular Health   Also, make sure to join the Pitch Session on June 2 at 2:30 PM, and connect with other like-minded, innovative start-ups such as AATec Medical and Mallia Therapeutics.   We can also recommend checking out the latest scientific posters during the breaks, including:    Secarna Pharmaceuticals: “Leading independent European antisense drug discovery & development company”  AATec Medical: “Novel Therapeutics for Globally Increasing Respiratory Diseases”   Schedule a meeting with our MC Services colleagues Eva Bauer, Dr. Cora Kaiser, Regina Lutz and Philipp Streng to find out more about how we support Life Science companies with expert Corporate Communications and Investor Relations insights: https://lnkd.in/d6ikVBPw   You can find the full agenda and the latest news from BayOConnect here: https://lnkd.in/dGMqmzYS #BayOConnect #LifeSciences #CorporateCommunications #InvestorRelations #MCServices #Networking #Biotech #Startup #Bayern #BioM 

The life-science ecosystem of Wallonia (Southern Belgium) was showcased at the LSX World Congress by a panel of experts: Benoit Kenda, VP and Early Solution Partnering Head at UCB; Amel Tounsi, CEO of Bridge to Health; and Marc Foidart, Executive Chairman of EyeD Pharma. They offered a fresh perspective on the current investment and partnering landscapes within Europe, with a focus on Wallonia, Belgium. Find out more on the strategies and challenges involved in scaling up biotech innovations, the strengths and characteristics of Belgium and Wallonia's biotech ecosystem and the benefits and advantages to forming new partnerships within Belgium and the Walloon region. We are proud to have our life sciences ecosystem represented by such an impressive group of experts! UCB Bridge to Health (B2H) EyeD Pharma Wallonie Bruxelles International AWEX UK Wallonie-Bruxelles International - Research and Innovation Noshaq Pascale Delcomminette Bioxodes convEyXO EXO Biologics CorQuest MedTech Allyfe Gabi SmartCare Bio-Sourcing ODIX medical Amyl Therapeutics Bloomlife Inc neuroClues #biotech #innovation #investment #healthtech #healthcarerevolution #lifesciences

September 30 - October 1! Fierce Biotech Summit in the Seaport. ‘This two-day summit brings together the brightest minds in biotech to exchange groundbreaking ideas and real-world applications. Attendees will have the chance to delve into critical discussions on the latest industry trends, including the biotech IPO outlook, developments in cell therapy and the transition from corporate communications to corporate affairs. Experts in the industry will also dive deep into how the industry has navigated regulatory challenges and market changes through strategic deals and innovative approaches.’ #biotech #biotechnology #biotechnologie #networking #likeandshare